Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Annals of hematology

Volumn 91, Issue 1, 2012, Pages 33-38

  Cashen, Amanda ^a   Juckett, Mark ^b   Jumonville, Alcee ^b   Litzow, Mark ^b   Flynn, P J ^b   Eckardt, John ^b   LaPlant, Betsy ^b   Laumann, Kristina ^b   Erlichman, Charles ^b   DiPersio, John ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BELINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

AGED; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84857386285     PISSN: None     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1240-1     Document Type: Article

References (0)